BioCentury | Jan 12, 2021
Finance

Diverse syndicate stands behind EQRx’s mission with $500M series B round

...rights to CDK4/6 inhibitor lerociclib and with Jiangsu Hansoh Pharmaceutical Co. Ltd....
BioCentury | Oct 28, 2020
Deals

In third cancer deal, EQRx aims to bring down cost of PD-1, PD-L1 inhibitors

...$20 million up front and up to $290 million in milestones, plus royalties; and with Jiangsu Hansoh Pharmaceutical Co. Ltd....
BioCentury | Jul 23, 2020
Deals

EQRx brings in next-in-class CDK4/6, EGFR inhibitors in bid for radically cheaper drugs

...milestone payments of up to $290 million. EQRx received ex-China rights to Ameile almonertinib from Jiangsu Hansoh Pharmaceutical Co. Ltd....
...and regulatory milestones, plus commercial milestones and royalties. Karen Tkach Tuzman, Associate Editor EQRx Inc. G1 Therapeutics Inc. Borisy drug pricing Jiangsu Hansoh Pharmaceutical Co. Ltd....
BioCentury | May 8, 2019
Company News

May 8 Company Quick Takes: Takeda selling Shire eye drug to Novartis in $3.4B deal; plus BioNTech, Third Rock’s Thrive and more

...Writers Elizabeth Eaton, Sandi Wong and Chris Lieu Xiidra, lifitegrast (SAR 1118, SHP606) Amgen Inc. BioNTech AG Chiesi Farmaceutici S.p.A. Jiangsu Hansoh Pharmaceutical Co. Ltd. Johnson...
BioCentury | Sep 7, 2018
Financial News

Hansoh files to list on Hong Kong exchange

...capital pre-IPO. In 2016, the firm invested $179.9 million in Hansoh. Jiangsu Hansoh Pharmaceutical Co. Ltd., Lianyungang, China Allison Johnson Hillhouse Capital Jiangsu Hansoh Pharmaceutical Co. Ltd. Hong...
BioCentury | Jul 21, 2017
Financial News

Uni-Bio raises HK$141.8M in private placement

...secretagogue Glufast from Kissei Pharmaceutical Co. Ltd. (Tokyo:4547). Uni-Bio has rights to the generic from Jiangsu Hansoh Pharmaceutical Co. Ltd....
BioCentury | Jul 18, 2017
Financial News

Uni-Bio raises HK$141.8M in private placement

...secretagogue Glufast from Kissei Pharmaceutical Co. Ltd. (Tokyo:4547). Uni-Bio has rights to the generic from Jiangsu Hansoh Pharmaceutical Co. Ltd....
BioCentury | Dec 7, 2015
Company News

Jiangsu Hansoh Pharmaceutical, Uni-Bio Science Group deal

...milestones. Uni-Bio declined to provide further financial terms, and Jiangsu did not respond to inquiries. Jiangsu Hansoh Pharmaceutical Co. Ltd....
BioCentury | Nov 25, 2015
Company News

Uni-Bio, Jiangsu Hansoh in diabetes deal

...Uni-Bio Science Group Ltd. (HKSE:690) gained exclusive, worldwide rights to mitiglinide from Jiangsu Hansoh Pharmaceutical Co. Ltd. (Lianyungang, China). Uni-Bio...
Items per page:
1 - 9 of 9
BioCentury | Jan 12, 2021
Finance

Diverse syndicate stands behind EQRx’s mission with $500M series B round

...rights to CDK4/6 inhibitor lerociclib and with Jiangsu Hansoh Pharmaceutical Co. Ltd....
BioCentury | Oct 28, 2020
Deals

In third cancer deal, EQRx aims to bring down cost of PD-1, PD-L1 inhibitors

...$20 million up front and up to $290 million in milestones, plus royalties; and with Jiangsu Hansoh Pharmaceutical Co. Ltd....
BioCentury | Jul 23, 2020
Deals

EQRx brings in next-in-class CDK4/6, EGFR inhibitors in bid for radically cheaper drugs

...milestone payments of up to $290 million. EQRx received ex-China rights to Ameile almonertinib from Jiangsu Hansoh Pharmaceutical Co. Ltd....
...and regulatory milestones, plus commercial milestones and royalties. Karen Tkach Tuzman, Associate Editor EQRx Inc. G1 Therapeutics Inc. Borisy drug pricing Jiangsu Hansoh Pharmaceutical Co. Ltd....
BioCentury | May 8, 2019
Company News

May 8 Company Quick Takes: Takeda selling Shire eye drug to Novartis in $3.4B deal; plus BioNTech, Third Rock’s Thrive and more

...Writers Elizabeth Eaton, Sandi Wong and Chris Lieu Xiidra, lifitegrast (SAR 1118, SHP606) Amgen Inc. BioNTech AG Chiesi Farmaceutici S.p.A. Jiangsu Hansoh Pharmaceutical Co. Ltd. Johnson...
BioCentury | Sep 7, 2018
Financial News

Hansoh files to list on Hong Kong exchange

...capital pre-IPO. In 2016, the firm invested $179.9 million in Hansoh. Jiangsu Hansoh Pharmaceutical Co. Ltd., Lianyungang, China Allison Johnson Hillhouse Capital Jiangsu Hansoh Pharmaceutical Co. Ltd. Hong...
BioCentury | Jul 21, 2017
Financial News

Uni-Bio raises HK$141.8M in private placement

...secretagogue Glufast from Kissei Pharmaceutical Co. Ltd. (Tokyo:4547). Uni-Bio has rights to the generic from Jiangsu Hansoh Pharmaceutical Co. Ltd....
BioCentury | Jul 18, 2017
Financial News

Uni-Bio raises HK$141.8M in private placement

...secretagogue Glufast from Kissei Pharmaceutical Co. Ltd. (Tokyo:4547). Uni-Bio has rights to the generic from Jiangsu Hansoh Pharmaceutical Co. Ltd....
BioCentury | Dec 7, 2015
Company News

Jiangsu Hansoh Pharmaceutical, Uni-Bio Science Group deal

...milestones. Uni-Bio declined to provide further financial terms, and Jiangsu did not respond to inquiries. Jiangsu Hansoh Pharmaceutical Co. Ltd....
BioCentury | Nov 25, 2015
Company News

Uni-Bio, Jiangsu Hansoh in diabetes deal

...Uni-Bio Science Group Ltd. (HKSE:690) gained exclusive, worldwide rights to mitiglinide from Jiangsu Hansoh Pharmaceutical Co. Ltd. (Lianyungang, China). Uni-Bio...
Items per page:
1 - 9 of 9